Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline

Executive Summary

Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.

You may also be interested in...



Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost

Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.

Facing Up To A Patent Cliff: Indivior Plans For Loss of Suboxone Film Exclusivity

With sales of its largest-selling product under threat from generic competition, a couple of new products and cost cuts are put forward to reinvigorate Indivior, a leader in addiction therapies.

Addex Completes Turnaround, Prepares For Phase III Dyskinesia Study

Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC100137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel